“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry

PURPOSE: PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in patients with heart failure and reduced ejection fraction (HF-REF). How widely applicable sacubitril/valsartan treatment is in unselected patients with HF-REF is not known. We examined eligibility of patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Drugs Ther
Hlavní autoři: Simpson, Joanne, Benson, L., Jhund, P. S., Dahlström, U., McMurray, J. J. V., Lund, L. H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538576/
https://ncbi.nlm.nih.gov/pubmed/30903545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06873-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky